Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension of lersivirine in HIV-1
NCT01254656Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of lersivirine in human immunodeficiency virus type 1 infection (HIV-1) (6 arms), sponsored by Pfizer. Primary endpoint: Participants With Plasma HIV-1 RNA Level <50 Copies/mL at 144 weeks. Started Feb 2011; status: terminated.
02
Drugs
lersivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01254656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254656.